Regulatory Approvals Signal It Is Time to Consider Investing in Cambridge Heart In. (CAMH.OB) Stock
The stock is tantalizing at $1.30 on February 20 2008 against a 52-week range of $4.60-0.75. There is strong stock investment logic behind this enticing trend as the management chalks up regulatory clearances in the most strategic health care markets. The company appears set to become a part of standard preventive care for all people at risk of heart failure. The company is involved in the non-invasive diagnosis of serious heart conditions. This is a key growth area of the preventive healthcare market all over the world. Obesity, diabetes, and sedentary lifestyles mean that increasing numbers of people are at…